Currently, the only approved and available complement-targeting therapies are eculizumab and ravulizumab, both of which are monoclonal antibodies targeting C5. Eculizumab targets glomerular inflammation but has no effect on complement deposition.
Prednisone, a corticosteroid, is often added to nonspecific immunosuppressive agents, especially mycophenolate mofetil, to augment their efficacy. In general, patients experience higher response rates with the addition of a corticosteroid to immunosuppressive therapy than with immunosuppressive agents or corticosteroids alone.
Antibiotics are used to control local symptoms and to prevent spread of infection in cases of acute infection associated glomerulonephritis.
Learn more about immunosuppressive therapy.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: A. Brent Alper. Fast Five Quiz: C3G Management - Medscape - Apr 24, 2023.